AXON ENTERPRISE, INC. annual report, FY2021

Business context and reporting period

Axon Enterprise, Inc. filed its Form 10-K for the fiscal year ended December 31, 2021. Axon provides conducted-energy devices, body-worn and in-vehicle cameras, digital evidence management, productivity software, real-time operations software, and related services to public-safety, government, commercial, and consumer markets.

The company reports two segments: TASER and Software and Sensors. Its strategy emphasizes recurring SaaS revenue, integrated hardware and software bundles, international expansion, new customer markets, and increased manufacturing capacity.

Key financial metrics

Metric	2021	2020	Change
Net sales	$863.4 million	$681.0 million	26.8% increase
Product revenue	$608.5 million	$500.3 million	21.6% increase
Service revenue	$254.9 million	$180.8 million	41.0% increase
Gross margin	$540.9 million; 62.7%	$416.3 million; 61.1%	Margin increased 160 basis points
Loss from operations	$(168.1) million; (19.5%)	$(14.2) million; (2.1%)	Loss widened materially
Net loss	$(60.0) million; $(0.91) per share	$(1.7) million; $(0.03) per share	Loss widened
Adjusted EBITDA	$179.2 million	$135.7 million	32.0% increase
Cash flow from operations	$124.5 million	$38.5 million	Increase of $86.0 million

Revenue was 80% U.S. and 20% international. TASER revenue increased 19.2% to $436.9 million, while Software and Sensors revenue increased 35.6% to $426.5 million. Axon Evidence and cloud services revenue across both segments totaled $255.2 million, compared with $179.7 million in 2020.

Annualized recurring revenue from monthly recurring license, integration, warranty, and storage revenue was $327.5 million at December 31, 2021.

Operating expenses increased 64.7% to $709.0 million. SG&A rose 67.6% to $515.0 million and R&D rose 57.5% to $194.0 million. Stock-based compensation expense increased to $303.3 million from $133.6 million, principally because of the CEO Performance Award and the XSPP.

Liquidity, capital resources, and debt

Cash and cash equivalents were $356.3 million at December 31, 2021, up from $155.4 million.
Cash, cash equivalents, and investments totaled $402.1 million, down from $652.7 million, primarily reflecting investment portfolio changes and strategic investments.
Operating cash flow was $124.5 million. Investing activities provided $252.6 million, including net investment proceeds, while financing activities used $174.2 million.
Accounts receivable and contract assets increased substantially, reflecting higher sales and subscription arrangements. Inventory increased to $108.7 million from $90.0 million.
Axon had no borrowings under its $50.0 million unsecured revolving credit facility. Outstanding letters of credit reduced available borrowing to $43.9 million. The facility matures December 31, 2023.
The company reported no long-term debt or financing lease obligations at year-end.
Contractual obligations totaled $357.9 million, including $328.4 million of purchase obligations and $29.4 million of operating lease obligations.

Material changes versus the prior comparable period

Revenue growth was led by Software and Sensors, particularly Axon Evidence and cloud services, as well as Axon Body cameras, while TASER growth was driven by TASER 7 devices and cartridges.
Gross margin improved to 62.7% from 61.1%. TASER segment gross margin rose to 65.7%; Software and Sensors gross margin was broadly stable at 59.5%.
Despite higher gross profit, operating losses expanded substantially because of increased stock compensation, headcount growth, sales investments, R&D spending, and cloud infrastructure costs.
Approximately $35.0 million of TASER 7 revenue and $15.5 million of Axon Body 3 revenue were delayed by component and supply-chain constraints and were expected to be recognized in the first half of 2022.
Backlog increased to $2.4 billion from $1.5 billion. Software and Sensors accounted for $2.35 billion of the year-end backlog, with approximately $510.8 million expected to be recognized over the following 12 months.
Remaining performance obligations were approximately $2.8 billion; management expected to recognize 15% to 20% over the next 12 months, subject to deployment, appropriation, and cancellation risks.
Axon raised $105.5 million of net proceeds through its at-the-market equity offering and issued shares in connection with employee equity awards and option exercises.

Guidance, outlook, risks, contingencies, and unusual items

Management expected approximately $1.0 billion of revenue for 2022 and capital expenditures of approximately $135 million to $160 million. This included approximately $85 million for a new Scottsdale manufacturing and office campus and approximately $40 million for TASER capacity expansion and automation.

On February 23, 2022, Axon entered into a construction management agreement with a maximum guaranteed price of approximately $149.7 million. Construction was expected to begin by May 3, 2022, with completion by July 25, 2024.

Supply-chain availability, supplier decommitments, semiconductor shortages, freight costs, geopolitical developments, and tariffs could constrain production and margins.
Government customers may delay, cancel, or decline to renew contracts because of budget appropriations, political constraints, termination-for-convenience provisions, or economic pressure.
Subscription growth increases deferred revenue and contract assets and may delay cash collection relative to revenue recognition, increasing credit and working-capital exposure.
The company faces product-liability litigation involving TASER devices and is self-insured for the first $5.0 million of claims made after 2014.
The FTC’s enforcement action concerning Axon’s 2018 acquisition of Vievu remained unresolved. Potential remedies could include divestiture of Vievu and other assets. No liability was recorded because the outcome could not be predicted.
Axon’s Supreme Court challenge to the FTC’s administrative process was accepted for review in January 2022; a decision was not expected until early 2023.
Privacy, cybersecurity, data protection, regulatory, export-control, product-safety, intellectual-property, foreign-exchange, and international-operating risks remain material.
Unrecognized tax benefits were $18.2 million at year-end and were expected to increase by approximately $0.7 million within 12 months.
Interest and other income included a $40.9 million gain from observable price changes in strategic investments, partly offset by a $17.8 million unrealized loss on Cellebrite marketable securities.
The company recognized $303.3 million of stock-based compensation, including significant expense related to performance-based CEO and employee awards. This materially reduced GAAP operating income but was excluded from Adjusted EBITDA.

Important facts for investors to verify

Whether 2022 revenue approaches management’s approximately $1.0 billion outlook and whether delayed TASER 7 and Axon Body 3 shipments are recognized as expected.
The conversion of the $2.4 billion backlog and $2.8 billion of remaining performance obligations into invoiced revenue and cash, including the effect of cancellations and government appropriations.
Whether supply-chain normalization supports planned revenue growth without materially reducing gross margins or increasing inventory write-downs.
The cash requirements and execution risk associated with the Scottsdale campus and other planned capital expenditures.
The continuing impact of CEO Performance Award and XSPP stock-based compensation on GAAP earnings, share dilution, and cash tax payments.
The outcome and potential remedies in the FTC litigation involving Vievu.
Growth and profitability of Axon Evidence and other recurring software services, including cloud infrastructure and professional-services costs.
Credit exposure from increased accounts receivable and contract assets, as well as the concentration of uninsured cash deposits at three institutions.
The company’s ability to maintain positive operating cash flow while reporting GAAP operating losses and funding growth investments.